Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06193317 · ClinicalTrials.gov registry record · NA
Effects of taVNS on Fibromyalgia Pain
A NA study, sponsored by Spaulding Rehabilitation Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 152
- Enrollment target
NCT06193317: Clinical Trial NA study, sponsored by Spaulding Rehabilitation Hospital.
NCT06193317 is a NA study that has not yet begun recruiting, run by Spaulding Rehabilitation Hospital. The registered enrollment target is 152 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06193317, a NA study, has not yet begun recruiting, sponsored by Spaulding Rehabilitation Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
Study Summary
Transauricular vagus nerve stimulation (taVNS) is a newer delivery system, using a non-invasive stimulation device placed at the ear's concha. TaVNS is a portable, safe, and low-cost intervention, and according to some studies, taVNS may influence nociception and pain perception, which can lead to potential applications for various painful illnesses, including fibromyalgia (FM). This trial aims to investigate the clinical effects of taVNS on pain control in FM subjects.
Primary Outcome
Brief Pain Inventory (BPI) is a short self-assessment questionnaire that provides information on various dimensions of pain including how pain developed, the types of pain a patient experiences, time of day pain is experienced, as well as current ways of alleviating pain. The BPI also includes the Visual Analog Scale (VAS) Pain scale, a simple 10-point scale (0 = ''no pain'', 10 = ''pain as bad as you can imagine'') measuring patients' pain, on average and at the present time. The BPI provides i
Interventions
- DEVICE Transauricular vagus nerve stimulation (taVNS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2029-05-01 |
| Phase | NA |
What is known before NCT06193317 opens enrollment
NCT06193317 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Transauricular vagus nerve stimulation (taVNS) is the first listed.
NCT06193317 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06193317 about?
NCT06193317 is a clinical study titled "Effects of taVNS on Fibromyalgia Pain". Transauricular vagus nerve stimulation (taVNS) is a newer delivery system, using a non-invasive stimulation device placed at the ear's concha. TaVNS is a portable, safe, and low-cost intervention, and according to some studies, taVNS may influence nociception and pain perception, which can lead to p...
What is the current status of trial NCT06193317?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 152 participants. The study started on 2026-06-01. Estimated completion is 2029-05-01.
What interventions are being tested in trial NCT06193317?
The interventions under investigation include: Transauricular vagus nerve stimulation (taVNS) (DEVICE).
Who is sponsoring clinical trial NCT06193317?
This trial is sponsored by Spaulding Rehabilitation Hospital, which has 101 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06193317's enrollment target sits among peer trials
152 658th of 2000 higher than 1,340 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI